217 related articles for article (PubMed ID: 15955621)
1. Thioredoxin reductase as a novel molecular target for cancer therapy.
Nguyen P; Awwad RT; Smart DD; Spitz DR; Gius D
Cancer Lett; 2006 May; 236(2):164-74. PubMed ID: 15955621
[TBL] [Abstract][Full Text] [Related]
2. Thioredoxin reductase regulates AP-1 activity as well as thioredoxin nuclear localization via active cysteines in response to ionizing radiation.
Karimpour S; Lou J; Lin LL; Rene LM; Lagunas L; Ma X; Karra S; Bradbury CM; Markovina S; Goswami PC; Spitz DR; Hirota K; Kalvakolanu DV; Yodoi J; Gius D
Oncogene; 2002 Sep; 21(41):6317-27. PubMed ID: 12214272
[TBL] [Abstract][Full Text] [Related]
3. Redox-sensitive signaling factors as a novel molecular targets for cancer therapy.
Pennington JD; Wang TJ; Nguyen P; Sun L; Bisht K; Smart D; Gius D
Drug Resist Updat; 2005 Oct; 8(5):322-30. PubMed ID: 16230045
[TBL] [Abstract][Full Text] [Related]
4. The thioredoxin-thioredoxin reductase system: over-expression in human cancer.
Lincoln DT; Ali Emadi EM; Tonissen KF; Clarke FM
Anticancer Res; 2003; 23(3B):2425-33. PubMed ID: 12894524
[TBL] [Abstract][Full Text] [Related]
5. Thioredoxin reductase as a potential molecular target for anticancer agents that induce oxidative stress.
Smart DK; Ortiz KL; Mattson D; Bradbury CM; Bisht KS; Sieck LK; Brechbiel MW; Gius D
Cancer Res; 2004 Sep; 64(18):6716-24. PubMed ID: 15374989
[TBL] [Abstract][Full Text] [Related]
6. Thioredoxin and thioredoxin reductase as redox-sensitive molecular targets for cancer therapy.
Pennington JD; Jacobs KM; Sun L; Bar-Sela G; Mishra M; Gius D
Curr Pharm Des; 2007; 13(33):3368-77. PubMed ID: 18045191
[TBL] [Abstract][Full Text] [Related]
7. Modulation of p53 dependent gene expression and cell death through thioredoxin-thioredoxin reductase by the Interferon-Retinoid combination.
Hu J; Ma X; Lindner DJ; Karra S; Hofmann ER; Reddy SP; Kalvakolanu DV
Oncogene; 2001 Jul; 20(31):4235-48. PubMed ID: 11464290
[TBL] [Abstract][Full Text] [Related]
8. Cell line-directed screening assay for inhibitors of thioredoxin reductase signaling as potential anti-cancer drugs.
Kunkel MW; Kirkpatrick DL; Johnson JI; Powis G
Anticancer Drug Des; 1997 Dec; 12(8):659-70. PubMed ID: 9448705
[TBL] [Abstract][Full Text] [Related]
9. Gold(III)-dithiocarbamato complexes induce cancer cell death triggered by thioredoxin redox system inhibition and activation of ERK pathway.
Saggioro D; Rigobello MP; Paloschi L; Folda A; Moggach SA; Parsons S; Ronconi L; Fregona D; Bindoli A
Chem Biol; 2007 Oct; 14(10):1128-39. PubMed ID: 17961825
[TBL] [Abstract][Full Text] [Related]
10. On the potential of thioredoxin reductase inhibitors for cancer therapy.
Urig S; Becker K
Semin Cancer Biol; 2006 Dec; 16(6):452-65. PubMed ID: 17056271
[TBL] [Abstract][Full Text] [Related]
11. Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy.
Tonissen KF; Di Trapani G
Mol Nutr Food Res; 2009 Jan; 53(1):87-103. PubMed ID: 18979503
[TBL] [Abstract][Full Text] [Related]
12. Diaryl chalcogenides as selective inhibitors of thioredoxin reductase and potential antitumor agents.
Engman L; Cotgreave I; Angulo M; Taylor CW; Paine-Murrieta GD; Powis G
Anticancer Res; 1997; 17(6D):4599-605. PubMed ID: 9494575
[TBL] [Abstract][Full Text] [Related]
13. Selenium and the thioredoxin redox system: effects on cell growth and death.
Powis G; Gasdaska JR; Gasdaska PY; Berggren M; Kirkpatrick DL; Engman L; Cotgreave IA; Angulo M; Baker A
Oncol Res; 1997; 9(6-7):303-12. PubMed ID: 9406236
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of thioredoxin reductase by mansonone F analogues: Implications for anticancer activity.
Liu Z; Huang SL; Li MM; Huang ZS; Lee KS; Gu LQ
Chem Biol Interact; 2009 Jan; 177(1):48-57. PubMed ID: 18822278
[TBL] [Abstract][Full Text] [Related]
15. Thioredoxin reductase inactivation as a pivotal mechanism of ifosfamide in cancer therapy.
Wang X; Zhang J; Xu T
Eur J Pharmacol; 2008 Jan; 579(1-3):66-73. PubMed ID: 18028906
[TBL] [Abstract][Full Text] [Related]
16. Thioredoxin reductase plays a critical role in IFN retinoid-mediated tumor-growth control in vivo.
Lindner DJ; Ma X; Hu J; Karra S; Kalvakolanu DV
Clin Cancer Res; 2002 Oct; 8(10):3210-8. PubMed ID: 12374691
[TBL] [Abstract][Full Text] [Related]
17. The thioredoxin/thioredoxin reductase redox system and control of cell growth.
Powis G; Oblong JE; Gasdaska PY; Berggren M; Hill SR; Kirkpatrick DL
Oncol Res; 1994; 6(10-11):539-44. PubMed ID: 7620223
[TBL] [Abstract][Full Text] [Related]
18. Redox active disulfides: the thioredoxin system as a drug target.
Kirkpatrick DL; Ehrmantraut G; Stettner S; Kunkel M; Powis G
Oncol Res; 1997; 9(6-7):351-6. PubMed ID: 9406241
[TBL] [Abstract][Full Text] [Related]
19. Cyclophosphamide as a potent inhibitor of tumor thioredoxin reductase in vivo.
Wang X; Zhang J; Xu T
Toxicol Appl Pharmacol; 2007 Jan; 218(1):88-95. PubMed ID: 17156807
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological activity of prodrug inhibitors of the thioredoxin-thioredoxin reductase system.
Wipf P; Lynch SM; Powis G; Birmingham A; Englund EE
Org Biomol Chem; 2005 Nov; 3(21):3880-2. PubMed ID: 16240002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
